ENTITY
Sino Biopharmaceutical

Sino Biopharmaceutical (1177 HK)

367
Analysis
Health Care • Hong Kong
Sino Biopharmaceutical is a leading, innovation-driven pharmaceutical conglomerate in China, focusing on the research, development, manufacturing, and sale of pharmaceutical products. The company specializes in therapeutic areas such as oncology, hepatology, respiratory, and cardiovascular diseases, offering both modernized Chinese and Western medicines. It was founded in 2000 and is headquartered in Wanchai, Hong Kong.
more
•14 Sep 2021 04:33

Asia Ex-Japan Positioning:  India & Tech at Record Highs

In this analysis, we provide a detailed overview of investor positioning among 96 active Asia Ex-Japan funds with combined AUM of $80bn.

Logo
394 Views
Share
•14 Jul 2026 08:30

CSPC Pharma (1093 HK): AstraZeneca SiRNA Deal Good, Approvals, New Launches Key For Future Growth

​CSPC Pharmaceutical partners with AstraZeneca to develop siRNA candidates for renal diseases. Licensing revenue will help compensate for revenue...

Logo
132 Views
Share
•03 Sep 2021 18:03

The Stocks to Own in Asia – Vol. 34

Our research team constantly reviews the Asian markets to try to find interesting ideas based on Fundamentals or Valuation or Momentum or Risk or...

Share
•08 Aug 2021 07:56

China Healthcare Weekly (Aug.6)

The insight mainly analyzed increasing short-term volatility in healthcare sector by newly released education policy, Nanjing COVID-19 outbreak,...

Logo
469 Views
Share
•04 Jul 2021 09:06

China Healthcare Weekly (July.2)

The article analyzed the new document about the development of TCM and western medicine,potential start time of VBP on biosimilar...

Logo
468 Views
Share
x